Beijing Bohui Innovation Technology Co Ltd (300318) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Beijing Bohui Innovation Technology Co Ltd ¥0.94, price ¥5.20, upside -81.9%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Beijing Bohui Innovation Technology Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥3.73 – ¥14.02 · fair‑value band ¥0.4900 – ¥1.40 · the ¥5.20 price screens above the ¥0.9400 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Beijing Bohui Innovation Technology Co in your weekly email
Every Wednesday you see whether Beijing Bohui Innovation Technology Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies.
Show more
Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. The company offers human immunoglobulin for rabies, tetanus, hepatitis B, and intravenous injections; albumin; human prothrombin complex; and vaccine for rabies. It also provides molecular platform, such as Automatic Real-time Fluorescent Nucleic Acid Cartridge Analyzer(BHQ-III), and GenPlex BHF-VI Nucleic Acid Chip Analyzer; Trace Element Analyzers; Fluorescence Immunoassay Analyzers, and Quantum Dot Analyzer; and detection kits for respiratory, intestinal, reproductive infections, as well as trace element testing, allergen testing, and others. In addition, the company offers mass spectrometers, plate readers, and standardized ion sources; and flash, process, and preparative purification systems. The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021. Beijing Bohui Innovation Biotechnology Group Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.
Stock analysis
Beijing Bohui Innovation Technology Co Ltd (300318) currently trades at ¥5.20, while our model-based Fair Value estimate is ¥0.9400, implying the stock looks roughly 453.1% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥1.44 per share, and 0 of the 4 models we run sit above the ¥5.20 price.
Bear case: the Dividend Discount group reads lowest at ¥0.5800, and 4 of the 4 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥0.4900 (bear) to ¥1.40 (bull), the price of ¥5.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Beijing Bohui Innovation Technology Co Ltd reported revenue of 825M CNY in FY2025 versus 715M CNY in FY2021, a compound +3.6%/yr. Reported net income was −91.9M CNY in FY2025.
Key figures
Market cap 4.2B CNY (≈ $634M) · P/S ratio 4.58 · EPS (TTM) ¥−0.1200 · Dividend yield 0.8% · Net margin −11.1% · Return on equity −8.0% · Return on assets (EBIT) −3.0% · Operating margin 1.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −82%, 300318 screens richer than that median.
Fair Value models
Bear ¥0.4900Fair Value ¥0.9400Bull ¥1.40
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.5% (2020) → 0.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Beijing Bohui Innovation Technology Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−82% · Bottom 25%
Profitability
Return on assets−1% · Above median
Net margin (TTM)−12% · Below median
Operating margin (TTM)1% · Above median
Growth and dividend
Revenue growth−6% · Below median
Dividend yield (TTM)0.8% · Below median
Balance sheet
Debt / equity0.34× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.49× · Cheapest 25%
P/S (TTM)0.78× · Cheapest 25%
EV/EBITDA21.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)83· sector 97
DIVIDEND (yield)17· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Beijing Bohui Innovation Technology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300318
Frequently asked questions
Is Beijing Bohui Innovation Technology Co Ltd (300318) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥0.9400 versus a price of ¥5.20, about −82% upside (overvalued).
What is the fair value of 300318?
Our model-based fair value for Beijing Bohui Innovation Technology Co Ltd is ¥0.9400 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥5.20.
What is the quality score of 300318?
Beijing Bohui Innovation Technology Co Ltd has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Bohui Innovation Technology Co Ltd (300318)?
Our model-based price target is the fair value of ¥0.9400 (as of Sep 23, 2026) from 4 valuation models. Cautious scenario ¥0.4900, optimistic scenario ¥1.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Bohui Innovation Technology Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.9400, about −82% upside versus a price of ¥5.20 (overvalued). Cautious scenario ¥0.4900, optimistic scenario ¥1.40. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Bohui Innovation Technology Co Ltd (300318)?
Beijing Bohui Innovation Technology Co Ltd reported trailing-twelve-month revenue of about 813M CNY (latest available figure, as of Sep 23, 2026).
Does Beijing Bohui Innovation Technology Co Ltd pay a dividend?
Beijing Bohui Innovation Technology Co Ltd currently shows a dividend yield of about 0.84% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Beijing Bohui Innovation Technology Co Ltd (300318)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Bohui Innovation Technology Co Ltd it is ¥0.9400 per share (as of Sep 23, 2026), against a price of ¥5.20. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Beijing Bohui Innovation Technology Co Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 300318 trades above its calculated fair value: price ¥5.20, fair value ¥0.9400, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300318?
No. The price is what the market pays today (¥5.20); the fair value is what the company's own numbers justify (¥0.9400). For Beijing Bohui Innovation Technology Co Ltd the two are ¥4.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Bohui Innovation Technology Co Ltd worth?
The market values Beijing Bohui Innovation Technology Co Ltd at about 4.2B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥5.20; our models calculate a fair value of ¥0.9400 per share.
What do the bullish and bearish scenarios say about 300318?
Our models span a range for Beijing Bohui Innovation Technology Co Ltd: cautious scenario ¥0.4900, base ¥0.9400, optimistic ¥1.40 per share (as of Sep 23, 2026, price ¥5.20). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beijing Bohui Innovation Technology Co Ltd (300318)?
Balance-sheet figures for Beijing Bohui Innovation Technology Co Ltd (as of Sep 23, 2026): return on equity −8.0%, debt of 0.34 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is 300318 from its 52-week high?
Beijing Bohui Innovation Technology Co Ltd trades at ¥5.20, about 36% below its 52-week high of ¥8.17 and 24% above the low of ¥4.18 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.9400 is for.
Which stocks are comparable to Beijing Bohui Innovation Technology Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Bohui Innovation Technology Co Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price ¥5.20, calculated fair value ¥0.9400 (−82%), Quality Score 32/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300318 calculated?
We run Beijing Bohui Innovation Technology Co Ltd through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.9400, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Beijing Bohui Innovation Technology Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Bohui Innovation Technology Co Ltd (300318)?
The closing price on Sep 22, 2026 was ¥5.20. Our model-based fair value is ¥0.9400, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Bohui Innovation Technology Co Ltd right now?
The price sits above even our optimistic bull case (¥1.40). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥0.4900 to ¥1.40). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Beijing Bohui Innovation Technology Co Ltd
How large is the market capitalisation of Beijing Bohui Innovation Technology Co Ltd (300318)?
The market capitalisation of Beijing Bohui Innovation Technology Co Ltd is 4.2B CNY (≈ $634M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Bohui Innovation Technology Co Ltd (300318)?
The price-to-sales ratio of Beijing Bohui Innovation Technology Co Ltd is 4.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing Bohui Innovation Technology Co Ltd (300318)?
Earnings per share at Beijing Bohui Innovation Technology Co Ltd are ¥−0.1200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Beijing Bohui Innovation Technology Co Ltd (300318)?
The dividend yield of Beijing Bohui Innovation Technology Co Ltd is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beijing Bohui Innovation Technology Co Ltd (300318)?
The net margin of Beijing Bohui Innovation Technology Co Ltd is −11.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Bohui Innovation Technology Co Ltd (300318)?
The return on equity (ROE) of Beijing Bohui Innovation Technology Co Ltd is −8.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Bohui Innovation Technology Co Ltd (300318)?
On an EBIT basis the return on assets of Beijing Bohui Innovation Technology Co Ltd is −3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Bohui Innovation Technology Co Ltd (300318)?
The operating margin of Beijing Bohui Innovation Technology Co Ltd is 1.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Bohui Innovation Technology Co Ltd (300318)?
Revenue at Beijing Bohui Innovation Technology Co Ltd is growing −5.8% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beijing Bohui Innovation Technology Co Ltd (300318)?
Earnings per share at Beijing Bohui Innovation Technology Co Ltd are growing +915% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Beijing Bohui Innovation Technology Co Ltd (300318) generate?
The free cash flow of Beijing Bohui Innovation Technology Co Ltd is −292M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Beijing Bohui Innovation Technology Co Ltd (300318) carry?
The net debt of Beijing Bohui Innovation Technology Co Ltd is 720M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Beijing Bohui Innovation Technology Co Ltd in the live analysis
One click puts Beijing Bohui Innovation Technology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
